Reagents News and Research

RSS

'Pool testing' for COVID-19 may help increase testing capacities across the globe

Now, a team of researchers at the German Red Cross Blood Donor Service and the Institute for Medical Virology at the University Hospital Frankfurt at Goethe University have developed a pool testing procedure that will make it possible to rapidly increase worldwide testing capacities for SARS-CoV-2.

1 Apr 2020

CELLINK receives healthcare consumables order of SEK 5,200,000

CELLINK AB (publ) has received an order for consumables for healthcare through an order from the National Board of Health and Welfare in Sweden, the order value is a total of 5,200,000 SEK.

From CELLINK 31 Mar 2020

Researchers find new strategy for developing tissue regeneration scaffolds

In Japan, an increase in the aging population has exacerbated the demand for regenerative medicine to address increasingly common diseases, such as knee osteoarthritis.

31 Mar 2020

INTEGRA, BioTools and Sullivan Nicolaides Pathology work together to accelerate COVID-19 testing

The global COVID-19 pandemic has placed unprecedented demands on pathology services to test patient samples for the novel SARS-CoV-2 coronavirus alongside their pre-existing respiratory virus panels.

From INTEGRA Biosciences 31 Mar 2020

Gene therapy investigators can greatly benefit from National Gene Vector Biorepository

Gene therapy investigators can greatly benefit from the resources and services provided by the National Gene Vector Biorepository, housed at the Indiana University School of Medicine.

27 Mar 2020

Russian researchers explain why new pathogenic viruses are so hard to detect

In a recently published fundamental review dedicated to the diagnostics of viral infections, a Russian research team featuring MIPT researchers was the first to systematically describe and summarize the cutting-edge technologies in the rapidly developing field of genetics.

25 Mar 2020

HORIBA Medical’s Yumizen G200 hemostasis device validated for use with UK NEQAS BC samples

HORIBA UK Ltd, Medical announces that a study has shown that UK National External Quality Assessment Scheme for Blood Coagulation external quality assessment lyophilized plasma samples can be tested on its Yumizen G200 hemostasis instrument.

From HORIBA Medical 20 Mar 2020

India gives Roche Diagnostics the license to conduct coronavirus tests, looks to delay disease progression

Following the news that the Drug Controller General of India has given license to Roche Diagnostics India to conduct coronavirus tests, Rohit Anand, Medical Devices Analyst at GlobalData, a leading data and analytics company, offers his view.

From Roche Sequencing and Life Science 20 Mar 2020

Gyrolab technology to be incorporated into Jefferson Institute for Bioprocessing specialized teaching curriculum and training programs

Gyros Protein Technologies and JIB announced that Gyrolab xPlore™ immunoassay system from Gyros Protein Technologies will be integrated into JIB’s curriculum.

From Gyros Protein Technologies AB 17 Mar 2020

Testing shortages force extreme shift in strategy by local health officials

Public health officials in California's state capital region announced this week they have stopped tracing the contacts of patients diagnosed with the novel coronavirus. They've also ceased recommending quarantines for residents exposed to people confirmed to have the virus.

13 Mar 2020

Single-drug therapy can attack several cellular targets using different modes of action

Clinicians combat the drug resistances of some cancer types by using a combination of different drugs. To make this approach more effective, chemists have designed a chemical conjugate that can simultaneously attack several cellular targets using different modes of action.

13 Mar 2020

New imaging agent illuminates cancerous tumors and surrounding cells

Scientists at Washington University School of Medicine in St. Louis have developed a new imaging agent that could let doctors identify not only multiple types of tumors but the surrounding normal cells that the cancer takes over and uses as a shield to protect itself from attempts to destroy it.

10 Mar 2020

Promega's custom manufacturing capabilities support rapid development of Logix Smart COVID-19 Test

Promega Corporation is being recognized by Utah-based Co-Diagnostics, Inc.

From Promega Corporation 26 Feb 2020

Both strands of microRNA cooperate to drive cancer growth and aggressiveness, research shows

Researchers long thought that only one strand of a double-stranded microRNA can silence genes. Though recent evidence has challenged that dogma, it's unclear what the other strand does, and how the two may be involved in cancer.

20 Feb 2020

A simple, straightforward approach to protein modification

Proteins are essential parts of organisms; thus, they are widely used in medicine, biology and chemistry. Enhancing their inherent properties by adding functional molecules to their structures is a common and important step in many fields.

14 Feb 2020

Hybrid microscope could bring cancer diagnosis into the digital era

By adding infrared capability to the ubiquitous, standard optical microscope, researchers at the University of Illinois at Urbana-Champaign hope to bring cancer diagnosis into the digital era.

12 Feb 2020

MR Solutions installs 3T PET-MR system at Western University’s ImPaKT facility

MR Solutions has installed a 3T PET-MR preclinical imaging system at Western University’s one of a kind ImPaKT Laboratory in Ontario.

From MR Solutions 5 Feb 2020

Coronavirus could spread explosively, tight control needed

The coronavirus may be taking a higher toll of life than we thought, say scientists, in a new study published on January 30, 2020, in The Lancet. But another startling new study based on mathematical modeling, published in the same journal, predicts that almost 76,000 people may have acquired the infection in Wuhan city, and that multiple epidemics in major connected cities inside and outside China may already be brewing. Yet the death rate is markedly low, in this case.

3 Feb 2020

Avacta demonstrates initial proof-of-concept for TMAC drug conjugates in pre-clinical study

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it has demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, TMAC, in a pre-clinical animal model of cancer.

From Avacta Life Sciences Ltd. 28 Jan 2020

Scientists visualize diabetes-related proteins at high resolution

Scientists have examined a key receptor for the first time at high resolution - broadening understanding of how it might function, and opening the door to future improvements in treating conditions such as type 2 diabetes.

24 Jan 2020